GABA(B) RECEPTOR AGONISTS AND ANTAGONISTS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1988
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
8174
Agency Tracking Number:
8174
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
6200 Freeport Ctr, Valtimore, MD, 21224
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institute:
n/a
Abstract
EVIDENCE SUGGESTS RECEPTORS MEDIATING CNS RESPONSES TO -AMINOBUTYRIC ACID (GABA) ARE HETEROGENEOUS AND THE DESIGNATIONS OF GABA(A) AND GABA(B) HAVE BEEN ADVANCED TO DIFFERENTIATE MAJOR RECEPTOR SUBTYPES. GABA(A) RECEPTORSARE ANTAGONIZED BY BICUCULLINE (BIC), LINKED TO A PICROTOXIN(PIC)-SENSITIVE CHLORIDE CHANNEL AND, AT LEAST PARTIALLY, ASSOCIATED WITH BENZODIAZEPINE (BZ) RECOGNITION SITES. IN CONTRAST, GABA(B) RECEPTORS ARE INSENSITIVE TO BIC AND PIC, DO NOT APPEAR TO BE FUNCTIONALLY LINKED TO BZ RECOGNITION SITES AND INFLUENCE VOLTAGE-SENSITIVE POTASSIUM AND CALCIUM CURRENTS. MULTIPLE AGONISTS AND ANTAGONISTS AREAVAILABLE TO EVALUATE GABA(A) RECEPTOR FUNCTION. HOWEVER, BACLOFEN (BAC) IS THE ONLY SELECTIVE AGONIST FOR GABA(A) RECEPTORS AND NO POTENT AND SPECIFIC ANTAGONISTS HAVE BEEN IDENTIFIED. BIOCHEMICAL AND PHYSIOLOGICAL EVIDENCE INDICATE GABA(A) RECEPTORS MEDIATE CLASSICAL SYNAPTIC NEUROTRANSMISSION WHEREAS GABA(B) RECEPTORS MAY BE INVOLVED IN MODULATION OF NEURONAL ACTIVITY. THUS, GABA MAY FUNCTIONIN A DUAL CAPACITY AS A NEURONTRANSMITTER AND NEUROMODULATORIN BRAIN. BAC REPRESENTS A WIDELY USED ANTISPASTIC AGENT. HOWEVER, DELETERIOUS SIDE-EFFECTS ATTENDING BAC ADMINISTRATION ARE DOCUMENTED. HETEROGENEITY AMONG GABA(B) RECEPTORS SUGGESTS THE POSSIBILITY OF DEVELOPING MORE SELECTIVE GABA(B) AGONISTS OF THERAPEUTIC POTENTIAL. FURTHERMORE, REASON EXISTS TO BELIEVE THAT GABA(B) ANTAGONISTS COULD BE OF THERAPEUTIC UTILITY, FOR INSTANCE, IN THE TREATMENT OF PARKINSON'S DISEASE OR AS CNS STIMULANTS. BECAUSE SUCH COMPOUNDS WOULD MODULATE RATHER THAN MIMICK (INHIBIT) NEUROTRANSMISSION, GABA(B) RECEPTOR AGONISTS AND ANTAGONISTSWOULD REPRESENT A SUBTLE APPROACH TO INFLUENCE GABA-MEDIATEDEVENTS IN BRAIN. THE PHASE I PROPOSAL SEEKS SUPPORT TO DEVELOP A PROGRAM TO IDENTIFY GABA(B) RECEPTOR AGONISTS AND ANTAGONISTS. METHODSWILL INCLUDE (1) IN VITRO LIGAND BINDING ASSAYS, (2) IN VITRO FUNCTIONAL ASSAYS AND (3) WHOLE ANIMAL TESTING. COMPOUNDS WILL BE SELECTED FROM NOVA'S CURRENT INVENTORY OF CHEMICALS. AGENTS IDENTIFIED AS HAVING THE DESIRED PHARMACOLOGICAL PROPERTIES WILL PROVIDE LEAD STRUCTURES TO INITIATE SYNTHETIC CHEMICAL EFFORTS IN THE PHASE II PORTION OF THE APPLICATION.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government